Current status and prospects of cytokine therapy for the treatment of renal cancer

Yoshihiro Wada, Kenichiro Tanoue, Wataru Takahashi, Yoshiaki Kawano, Masatoshi Eto

Research output: Contribution to journalArticle

Abstract

In this article, we review the issues related to cytokine therapy for the treatment of renal cancer. The situation of cytokine therapy in Japan is greatly different from that in other countries. In Japan, the use of molecular targeted-based drugs has increased rapidly since 2008, with a considerable amount of cytokine agents being used. Cytokine therapy significantly extends overall survival when nephrectomy is performed, resulting in good performance status (PS 0-1), in relatively younger patients with non-bulky metastatic nests. Cytokine therapy is expected to be more effective when used as a 1st-line treatment Molecular targeted-based therapy produces fewer cases of CR than cytokine therapy. The prognosis of Japanese metastatic renal cancer patients in the cytokine era was better than that of European and American patients. As for patients in the better risk group, when comparing the prognosis with cytokine therapy to that with molecular-targeted based therapy, the indications are that cytokine therapy should be chosen. We should always consider multidisciplinary treatment including metastasectomy, and not be confined to pharmacotherapy alone. The discovery of predictive markers in cytokine therapy is likely to result in the establishment of personal-tailored therapeutic strategies. Concurrent cytokine therapy comprising IFN- α plus IL-2 is more effective when disease metastasis is limited to the lung. As regards concurrent therapy comprising molecular-targeted based plus cytokine agents, Sorafenib plus IFN- α should be very likely to be useful. It is necessary to integrate and develop all available knowledge in order to maximize the effect of such available therapeutic agents including cytokine agents.

Original languageEnglish
Pages (from-to)236-249
Number of pages14
JournalNishinihon Journal of Urology
Volume74
Issue number5
Publication statusPublished - May 1 2012
Externally publishedYes

Fingerprint

Kidney Neoplasms
Cytokines
Molecular Targeted Therapy
Therapeutics
Japan
Metastasectomy
Nephrectomy
Interleukin-2

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Current status and prospects of cytokine therapy for the treatment of renal cancer. / Wada, Yoshihiro; Tanoue, Kenichiro; Takahashi, Wataru; Kawano, Yoshiaki; Eto, Masatoshi.

In: Nishinihon Journal of Urology, Vol. 74, No. 5, 01.05.2012, p. 236-249.

Research output: Contribution to journalArticle

Wada, Y, Tanoue, K, Takahashi, W, Kawano, Y & Eto, M 2012, 'Current status and prospects of cytokine therapy for the treatment of renal cancer', Nishinihon Journal of Urology, vol. 74, no. 5, pp. 236-249.
Wada, Yoshihiro ; Tanoue, Kenichiro ; Takahashi, Wataru ; Kawano, Yoshiaki ; Eto, Masatoshi. / Current status and prospects of cytokine therapy for the treatment of renal cancer. In: Nishinihon Journal of Urology. 2012 ; Vol. 74, No. 5. pp. 236-249.
@article{3c525678fde8461daba5362344df4d2f,
title = "Current status and prospects of cytokine therapy for the treatment of renal cancer",
abstract = "In this article, we review the issues related to cytokine therapy for the treatment of renal cancer. The situation of cytokine therapy in Japan is greatly different from that in other countries. In Japan, the use of molecular targeted-based drugs has increased rapidly since 2008, with a considerable amount of cytokine agents being used. Cytokine therapy significantly extends overall survival when nephrectomy is performed, resulting in good performance status (PS 0-1), in relatively younger patients with non-bulky metastatic nests. Cytokine therapy is expected to be more effective when used as a 1st-line treatment Molecular targeted-based therapy produces fewer cases of CR than cytokine therapy. The prognosis of Japanese metastatic renal cancer patients in the cytokine era was better than that of European and American patients. As for patients in the better risk group, when comparing the prognosis with cytokine therapy to that with molecular-targeted based therapy, the indications are that cytokine therapy should be chosen. We should always consider multidisciplinary treatment including metastasectomy, and not be confined to pharmacotherapy alone. The discovery of predictive markers in cytokine therapy is likely to result in the establishment of personal-tailored therapeutic strategies. Concurrent cytokine therapy comprising IFN- α plus IL-2 is more effective when disease metastasis is limited to the lung. As regards concurrent therapy comprising molecular-targeted based plus cytokine agents, Sorafenib plus IFN- α should be very likely to be useful. It is necessary to integrate and develop all available knowledge in order to maximize the effect of such available therapeutic agents including cytokine agents.",
author = "Yoshihiro Wada and Kenichiro Tanoue and Wataru Takahashi and Yoshiaki Kawano and Masatoshi Eto",
year = "2012",
month = "5",
day = "1",
language = "English",
volume = "74",
pages = "236--249",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "5",

}

TY - JOUR

T1 - Current status and prospects of cytokine therapy for the treatment of renal cancer

AU - Wada, Yoshihiro

AU - Tanoue, Kenichiro

AU - Takahashi, Wataru

AU - Kawano, Yoshiaki

AU - Eto, Masatoshi

PY - 2012/5/1

Y1 - 2012/5/1

N2 - In this article, we review the issues related to cytokine therapy for the treatment of renal cancer. The situation of cytokine therapy in Japan is greatly different from that in other countries. In Japan, the use of molecular targeted-based drugs has increased rapidly since 2008, with a considerable amount of cytokine agents being used. Cytokine therapy significantly extends overall survival when nephrectomy is performed, resulting in good performance status (PS 0-1), in relatively younger patients with non-bulky metastatic nests. Cytokine therapy is expected to be more effective when used as a 1st-line treatment Molecular targeted-based therapy produces fewer cases of CR than cytokine therapy. The prognosis of Japanese metastatic renal cancer patients in the cytokine era was better than that of European and American patients. As for patients in the better risk group, when comparing the prognosis with cytokine therapy to that with molecular-targeted based therapy, the indications are that cytokine therapy should be chosen. We should always consider multidisciplinary treatment including metastasectomy, and not be confined to pharmacotherapy alone. The discovery of predictive markers in cytokine therapy is likely to result in the establishment of personal-tailored therapeutic strategies. Concurrent cytokine therapy comprising IFN- α plus IL-2 is more effective when disease metastasis is limited to the lung. As regards concurrent therapy comprising molecular-targeted based plus cytokine agents, Sorafenib plus IFN- α should be very likely to be useful. It is necessary to integrate and develop all available knowledge in order to maximize the effect of such available therapeutic agents including cytokine agents.

AB - In this article, we review the issues related to cytokine therapy for the treatment of renal cancer. The situation of cytokine therapy in Japan is greatly different from that in other countries. In Japan, the use of molecular targeted-based drugs has increased rapidly since 2008, with a considerable amount of cytokine agents being used. Cytokine therapy significantly extends overall survival when nephrectomy is performed, resulting in good performance status (PS 0-1), in relatively younger patients with non-bulky metastatic nests. Cytokine therapy is expected to be more effective when used as a 1st-line treatment Molecular targeted-based therapy produces fewer cases of CR than cytokine therapy. The prognosis of Japanese metastatic renal cancer patients in the cytokine era was better than that of European and American patients. As for patients in the better risk group, when comparing the prognosis with cytokine therapy to that with molecular-targeted based therapy, the indications are that cytokine therapy should be chosen. We should always consider multidisciplinary treatment including metastasectomy, and not be confined to pharmacotherapy alone. The discovery of predictive markers in cytokine therapy is likely to result in the establishment of personal-tailored therapeutic strategies. Concurrent cytokine therapy comprising IFN- α plus IL-2 is more effective when disease metastasis is limited to the lung. As regards concurrent therapy comprising molecular-targeted based plus cytokine agents, Sorafenib plus IFN- α should be very likely to be useful. It is necessary to integrate and develop all available knowledge in order to maximize the effect of such available therapeutic agents including cytokine agents.

UR - http://www.scopus.com/inward/record.url?scp=84861828711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861828711&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84861828711

VL - 74

SP - 236

EP - 249

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 5

ER -